GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

Kuvatris Therapeutics PXMD · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

0.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2023

Net income

−$18.3m

FY2019FY2023

Free cash flow

−$10.8m

FY2019FY2023

Shareholders' equity

$3.4m

FY2019FY2023

Income statement

Fiscal years

FY2023FY2022FY2021FY2020FY2019
Research and development$3.9m$1.8m$2.2m$936,776$484,113
Operating income−$16.1m−$10.6m−$7.2m−$5.6m−$598,609
Net income−$18.3m−$14.8m−$13.0m−$8.5m−$598,609
Diluted earnings per share-2.47-20.91-1.30-0.85-0.06

Balance sheet

At each fiscal year end

FY2023FY2022FY2021FY2020FY2019
Total assets$5.7m$2.2m$648,866$1.1m$24,947
Cash and short-term investments$4.7m$1.9m$444,087$1.1m$24,947
Total liabilities$2.3m$2.1m$10.8m$5.8m$123,248
Debt$500.0m$173,543—$611,641—
Shareholders' equity$3.4m$108,800−$10.1m−$4.6m−$98,301
Shares outstanding7m1m10m10m10m

Cash flow

Fiscal years

FY2023FY2022FY2021FY2020FY2019
Cash from operations−$10.8m−$6.1m−$5.5m−$2.3m−$419,375
Free cash flow−$10.8m−$6.1m−$5.5m−$2.3m−$419,375
Dividends paid−$11.95bn−$35,000———

Latest quarters

By quarter end

Sept 2024Jun 2024Mar 2024Dec 2023Sept 2023Jun 2023Mar 2023Dec 2022
Operating income−$887,937−$3.0m−$3.7m−$4.4m−$4.4m−$3.4m−$4.0m−$5.0m
Net income−$876,642−$3.0m−$3.7m−$5.9m−$5.0m−$3.5m−$3.8m−$5.2m
Diluted earnings per share-0.08-0.28-0.34-0.80-0.68-0.47-0.52-7.37
Cash from operations—−$1.0m−$3.0m−$2.0m−$2.0m−$2.0m−$2.0m−$3.0m
Total assets$820,380$799,611$2.9m$5.7m$3.2m$5.1m$4.8m$2.2m
Cash and short-term investments—$324,486$1.6m$4.7m$1.2m$3.1m$4.0m$1.9m
Debt———−$500.0m$1.6m$1.7m$1.5m$173,543
Shareholders' equity−$1.9m−$1.8m$1.2m$3.4m−$536,919$2.3m$2.5m$108,800

Growth per year

Compound annual rate

3 years5 years10 years
Operating income42.6%——
Net income29.2%——

Share price return

Finished calendar years

2025202420232022
Return-99%-61%-95%-65%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 17-to-1 reverse split · 31 Oct 2023

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.